Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Yang Website

James C. Yang, M.D.

Selected Publications

1)  Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA.
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.
Blood. 122: 1399-410, 2013.
[Journal]
2)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma.
J. Clin. Oncol. [Epub ahead of print], 2013.
[Journal]
3)  Yang JC.
The adoptive transfer of cultured T cells for patients with metastatic melanoma.
Clin. Dermatol. 31: 209-19, 2013.
[Journal]
4)  Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC.
Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
Cancer Res. 72: 6119-29, 2012.
[Journal]
5)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
[Journal]
6)  Economou J, Yang J, Tomlinson J.
Townsend, Jr. C, Beauchamp R, Evers B, Mattox K, eds.
Tumor Immunology and Immunotherapy. In: Sabiston Textbook of Surgery. Volume 19th Edition.
Philadelphia: W.B. Saunders; 2012. p. Section 5, Chapter 31 [Book Chapter]
7)  Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, Van Waes C, Morgan RA, Dudley ME, Yang JC, Rosenberg SA, Kim HJ.
Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma.
Otolaryngol Head Neck Surg. 147: 744-9, 2012.
[Journal]
8)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
[Journal]
9)  Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ.
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Clin. Cancer Res. 18: 2039-47, 2012.
[Journal]
10)  Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling SK, Bernhardt G, Park JH, Yang JC, Sun PD, Singer A.
αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities.
Immunity. 36: 79-91, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 9/16/2013.